Evidence map›Paper›PMID 41127123›Full record

ArticleInfectious Disease Modelling2026

Travel-related importation risk of mpox from Hong Kong to Shenzhen in 2023: A modeling study.

Ruohan Chen, Jia Wan, Dongfeng Kong, Cong Niu, Zengyang Shao, Chijun Zhang, Mingda Xu, Yuan Bai, Eric Lau, Zhen Zhang and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious Disease Modelling, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ruohan ChenWHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region of China.
Jia WanShenzhen Center for Disease Control and Prevention, Shenzhen, China.
Dongfeng KongShenzhen Center for Disease Control and Prevention, Shenzhen, China.
Cong NiuShenzhen Center for Disease Control and Prevention, Shenzhen, China.
Zengyang ShaoWHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region of China.
Chijun ZhangInternational Business School, Guangdong University of Finance & Economics, Guangzhou, China.
Mingda XuSchool of Artificial Intelligence, Optics and Electronics (iOPEN), Northwestern Polytechnical University, Xi'an, China.
Yuan BaiWHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region of China.
Eric LauWHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region of China.
Zhen ZhangShenzhen Center for Disease Control and Prevention, Shenzhen, China.
Zhanwei DuWHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mpox, a viral zoonotic disease formerly known as monkeypox, has gained global attention following a multi-country outbreak in 2022-23, primarily linked to close intimate contact. In China, mpox cases surged in June 2023, with nearly a quarter of new cases concentrated in Guangdong Province, particularly Shenzhen. This study aimed to estimate the importation risk of mpox cases from Hong Kong to Shenzhen in 2023, utilizing cross-regional population mobility data from January to October 2023. The analysis focused on local transmission in Hong Kong and the probability of mpox importation into Shenzhen. Results revealed a significant importation risk, with over a 50 % chance of at least one travel-based mpox case from Hong Kong in June 2023. The study underscores the necessity of enhancing inbound surveillance for travelers from high mpox prevalence regions. It is suggested that regional governments implement tailored strategies, including enhanced surveillance and dynamic risk assessment for effective cross-border disease management, supported by robust monitoring and coordinated actions across jurisdictions.

Indexed as

Cross-boundary travelHong KongImportation riskInbound surveillanceMpoxShenzhen

Identifiers

PMID41127123
PMCPMC12537553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.